These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37220610)

  • 1. Advances in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia.
    Nannya Y; Viswabandya A; Lu P
    Blood Cell Ther; 2022 Dec; 5(Spec Edition):S25-S33. PubMed ID: 37220610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia.
    Tsirigotis P; Gkirkas K; Kitsiou V; Chondropoulos S; Athanassiades T; Thomopoulos T; Tsirogianni A; Stamouli M; Karagiannidi A; Siafakas N; Pappa V; Nagler A
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34070786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
    Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
    Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients.
    Greiner J; Götz M; Bunjes D; Hofmann S; Wais V
    J Clin Med; 2019 Dec; 9(1):. PubMed ID: 31878060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
    Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
    Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.
    Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment.
    Kreidieh F; Abou Dalle I; Moukalled N; El-Cheikh J; Brissot E; Mohty M; Bazarbachi A
    Int J Hematol; 2022 Sep; 116(3):330-340. PubMed ID: 35841458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant.
    Li Q; Lyu C; Liu M; Wang J; Mou N; Jiang E; Zhang R; Deng Q
    Cell Transplant; 2023; 32():9636897231158155. PubMed ID: 36879459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine.
    Visani G; Olivieri A; Malagola M; Brunori M; Piccaluga PP; Capelli D; Pomponio G; Martinelli G; Isidori A; Sparaventi G; Leoni P
    Leuk Lymphoma; 2006 Jun; 47(6):1091-102. PubMed ID: 16840201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering.
    Ye Y; Yang L; Yuan X; Huang H; Luo Y
    Front Oncol; 2021; 11():790299. PubMed ID: 35155192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
    J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New approaches in allogenic transplantation in AML.
    Pei X; Huang X
    Semin Hematol; 2019 Apr; 56(2):147-154. PubMed ID: 30926091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?
    Jiang H; Hu Y; Mei H
    Biomark Res; 2020 Nov; 8(1):66. PubMed ID: 33292685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: Deep molecular remissions post two separate CD19-targeted chimeric antigen receptor T-cell therapies do not prevent disease from relapsing in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Tang Y; Fei X; Yu X; Cao J; Wang L; Lei F
    Front Oncol; 2023; 13():1251738. PubMed ID: 38023231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of AML Relapse After Allo-HCT.
    Webster JA; Luznik L; Gojo I
    Front Oncol; 2021; 11():812207. PubMed ID: 34976845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT.
    Al Hamed R; Labopin M; Wu D; Gedde-Dahl T; Aljurf M; Forcade E; Salmenniemi U; Passweg J; Maertens J; Pabst T; Versluis J; Itäla-Remes M; Huang XJ; Van Gorkom G; Schroeder T; Sanz J; Blaise D; Reményi P; Schanz U; Esteve J; Gorin NC; Ciceri F; Mohty M
    Bone Marrow Transplant; 2024 Aug; ():. PubMed ID: 39095548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.
    Tsirigotis P; Byrne M; Schmid C; Baron F; Ciceri F; Esteve J; Gorin NC; Giebel S; Mohty M; Savani BN; Nagler A
    Bone Marrow Transplant; 2016 Nov; 51(11):1431-1438. PubMed ID: 27295272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.